Rogers Simon N, Monssen Camilla, Humphris Gerald M, Lowe Derek, Kanatas Anastasios
Faculty of Health and Social Care, Edge Hill University, Ormskirk, United Kingdom.
Liverpool Head and Neck Centre, Liverpool University Hospital Aintree, Liverpool, United Kingdom.
Front Psychol. 2021 Jul 16;12:671366. doi: 10.3389/fpsyg.2021.671366. eCollection 2021.
Fear of cancer recurrence (FCR) is recognized as a common concern for patients with head and neck cancer (HNC). The aim of this study is to describe in greater detail the demographic and clinical characteristics of HCN patients who indicate a high level of FCR in their review consultation. A pragmatic cluster-controlled trial was conducted between January 2017 and December 2018 at two UK HNC centers (Leeds and Liverpool) to test the efficacy of a prompt tool called the Patient Concerns Inventory (PCI). Patients completed the PCI and the UW-QOLv4 which included a single 5 category rating of FCR. Secondary statistical analyses focused on variables associated with high FCR. Two hundred and eighty-eight trial patients were recruited in this trial. At a median of 194 days after diagnosis and 103 days after the end of treatment 8% stated ( = 24) "I get a lot of fears of recurrence and these can really preoccupy my thoughts" and 3% ( = 8) "I am fearful all the time that my cancer might return, and I struggle with this." Thus, 11% ( = 32) responded in the worst two categories, 95% Confidence interval 7.7-15.3% for high FCR. Stepwise logistic regression resulted in female gender ( < 0.001), age ( = 0.007), and receiving financial benefits ( = 0.01) as independent predictors. Around one in ten HNC patients attending routine outpatient follow-up consultations report high FCR, however for female patients under the age of 55 the rate was one in three. This group requires specialist attention and could be the focus of a multicenter intervention trial.
癌症复发恐惧(FCR)被认为是头颈癌(HNC)患者的一个常见担忧。本研究的目的是更详细地描述在复诊咨询中显示出高度癌症复发恐惧的头颈癌患者的人口统计学和临床特征。2017年1月至2018年12月期间,在英国的两个头颈癌中心(利兹和利物浦)进行了一项实用的整群对照试验,以测试一种名为患者担忧量表(PCI)的快速工具的疗效。患者完成了PCI和UW-QOLv4,其中包括对癌症复发恐惧的单一5级评分。二次统计分析集中在与高度癌症复发恐惧相关的变量上。本试验招募了288名试验患者。在诊断后中位数194天和治疗结束后103天,8%(n = 24)的患者表示“我非常担心复发,这些真的会占据我的思绪”,3%(n = 8)的患者表示“我一直担心我的癌症可能会复发,我为此很苦恼”。因此,11%(n = 32)的患者在最差的两个类别中做出了回应,高度癌症复发恐惧的95%置信区间为7.7 - 15.3%。逐步逻辑回归分析得出女性性别(P < 0.001)、年龄(P = 0.